CBGA: The Mother of All Cannabinoids
Cannabinoid Biosynthesis, CBG Pharmacology, and the Biochemical Origin of Major Cannabinoids
Author: Christopher Lynch
Founder, True Hemp Science
Introduction
Cannabis produces a diverse class of secondary metabolites known as cannabinoids. More than one hundred phytocannabinoids have been identified in Cannabis sativa, but most originate from a single biochemical precursor: cannabigerolic acid (CBGA). CBGA occupies a central position in the cannabinoid biosynthetic pathway and functions as the substrate from which several major cannabinoids are formed. For this reason, CBGA is widely described as the mother cannabinoid.
In living cannabis plants, cannabinoids are synthesized predominantly in their acidic forms. Cannabinoids familiar to consumers—such as CBD and THC—are typically decarboxylation products derived from these acidic precursors. The plant does not produce CBD or THC directly. Instead, CBGA is enzymatically converted into acidic cannabinoids including tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA). Subsequent decarboxylation converts these compounds into their neutral forms.
This biosynthetic architecture explains the central biochemical role of CBGA. It also explains why cannabinoid ratios vary among cultivars. Genetic expression of cannabinoid synthase enzymes determines which pathways dominate during plant development.
Understanding CBGA is therefore essential for understanding the chemistry of cannabis itself.
Cannabinoid Biosynthesis
Cannabinoid biosynthesis occurs primarily in glandular trichomes located on the female inflorescences of the cannabis plant. These specialized secretory structures produce cannabinoids, terpenes, and other secondary metabolites.
The pathway begins with the synthesis of olivetolic acid, a polyketide-derived aromatic compound produced through condensation of hexanoyl-CoA with malonyl-CoA units. Olivetolic acid then undergoes prenylation through the enzyme geranylpyrophosphate:olivetolate geranyltransferase (GOT), producing cannabigerolic acid (CBGA).
CBGA serves as the primary branching point of the cannabinoid biosynthetic pathway.
Three oxidocyclase enzymes subsequently convert CBGA into distinct acidic cannabinoids:
• THCA synthase → tetrahydrocannabinolic acid (THCA)
• CBDA synthase → cannabidiolic acid (CBDA)
• CBCA synthase → cannabichromenic acid (CBCA)
Each enzyme catalyzes oxidative cyclization of CBGA into a structurally distinct cannabinoid acid.
This enzymatic competition determines the cannabinoid profile of a plant. Cultivars expressing strong THCA synthase activity accumulate THCA-rich chemotypes. Plants expressing CBDA synthase accumulate CBDA-dominant profiles typical of industrial hemp cultivars.
CBGA therefore functions as the metabolic substrate shared by multiple cannabinoid pathways.
CBGA as the Central Metabolic Precursor
CBGA occupies a singular position in cannabis metabolism because it is the direct biochemical precursor of several major cannabinoid classes. During plant development, CBGA concentrations decline as oxidocyclase enzymes convert the molecule into downstream products.
This explains why CBGA concentrations in mature cannabis flowers are often relatively low compared with THCA or CBDA. Most CBGA is consumed enzymatically during cannabinoid synthesis.
However, plant breeding has altered this dynamic. Modern breeding programs have produced CBG-dominant cultivars in which oxidocyclase activity is reduced or genetically modified. In these plants, CBGA is not efficiently converted into THCA or CBDA, allowing larger quantities of CBG to accumulate following decarboxylation.
Such cultivars demonstrate how genetic control of cannabinoid synthase enzymes determines chemotype expression.
Decarboxylation and the Formation of Neutral Cannabinoids
Cannabinoids produced by living plants contain a carboxyl group (-COOH) attached to the aromatic ring system. This functional group defines the acidic form of the molecule.
Exposure to heat, ultraviolet radiation, or prolonged storage can remove this carboxyl group through decarboxylation, converting cannabinoid acids into their neutral counterparts.
Examples include:
CBGA → CBG
CBDA → CBD
THCA → THC
CBCA → CBC
Decarboxylation is typically triggered during:
• combustion
• vaporization
• cooking
• extraction processes involving heat
The process alters molecular structure and receptor interaction profiles. Consequently, acidic and neutral cannabinoids may exhibit distinct pharmacological characteristics.
Because the plant produces cannabinoids primarily in acidic form, many researchers consider cannabinoid acids to represent the native biochemical state of cannabis phytochemistry.
Acidic vs Neutral Cannabinoids
The distinction between acidic and neutral cannabinoids is fundamental to cannabinoid science.
Acidic cannabinoids dominate the chemical composition of living cannabis plants. Neutral cannabinoids arise primarily through decarboxylation.
This distinction is summarized below.
| Acidic Cannabinoid | Neutral Cannabinoid | Conversion Mechanism |
|---|---|---|
| CBGA | CBG | Decarboxylation |
| CBDA | CBD | Decarboxylation |
| THCA | THC | Decarboxylation |
| CBCA | CBC | Decarboxylation |
Acidic cannabinoids possess additional molecular weight and polarity due to the carboxyl group. Removal of this group changes both molecular shape and receptor binding behavior.
Research on acidic cannabinoids remains limited compared with their neutral counterparts. However, increasing attention has been directed toward CBGA, CBDA, and THCA due to their presence in raw plant material and minimally heated extracts.
From a biochemical perspective, CBGA represents the starting point of cannabinoid diversification. Every major cannabinoid class produced by the plant originates from this molecule.
Â
The Endocannabinoid System
The endocannabinoid system (ECS) is a lipid signaling network involved in the regulation of numerous physiological processes including neurotransmission, immune signaling, metabolic regulation, and stress responses. The ECS consists of three principal components:
• cannabinoid receptors
• endogenous cannabinoid ligands
• metabolic enzymes responsible for ligand synthesis and degradation
Two receptors dominate ECS research: CB1 and CB2.
CB1 receptors are expressed primarily in the central nervous system. High densities occur in the cerebral cortex, hippocampus, basal ganglia, and cerebellum. These receptors regulate synaptic neurotransmitter release through presynaptic inhibition of calcium channels and activation of potassium channels.
CB2 receptors occur primarily in immune cells and peripheral tissues. They participate in immune signaling, inflammatory modulation, and cellular migration responses.
Endogenous ligands of the ECS include:
• anandamide (AEA)
• 2-arachidonoylglycerol (2-AG)
These molecules are synthesized on demand from membrane lipid precursors and act as retrograde neurotransmitters. Following receptor activation, they are degraded primarily by the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Phytocannabinoids derived from cannabis interact with this signaling system by modulating receptor activity or influencing enzymatic pathways associated with endogenous cannabinoids.
Pharmacological Properties of Cannabigerol (CBG)
Cannabigerol (CBG) is the decarboxylated neutral form of CBGA. Unlike Δ9-tetrahydrocannabinol (THC), CBG exhibits low affinity for CB1 receptors and does not produce the strong psychoactive effects associated with THC.
However, CBG demonstrates activity at several molecular targets beyond the classical cannabinoid receptors.
Pharmacological studies have reported interactions with:
• CB1 receptors (weak partial agonism or antagonism depending on context)
• CB2 receptors
• α2-adrenergic receptors
• 5-HT1A serotonin receptors
• transient receptor potential channels (TRPV1, TRPA1)
These receptor interactions suggest that CBG participates in multi-target pharmacology, a pattern common among plant-derived small molecules.
Experimental work has also identified moderate inhibition of anandamide reuptake by CBG. Increased extracellular anandamide concentrations may indirectly influence CB1 signaling in certain contexts.
Despite these findings, pharmacological characterization of CBG remains incomplete. Most data originate from in vitro studies or animal models, and human clinical evidence remains limited.
Cannabinoids and Cellular Signaling
Several cannabinoids have been investigated for their influence on cellular signaling pathways associated with inflammation and immune responses.
Research on CBG has examined interactions with transcription factors involved in inflammatory signaling. In particular, experimental models have investigated effects on pathways involving:
• NF-κB (nuclear factor kappa-B)
• JAK/STAT signaling pathways
These pathways regulate expression of cytokines and inflammatory mediators.
A 2025 study examining CBG in an atopic dermatitis model reported modulation of inflammatory responses through JAK/STAT and NF-κB related signaling mechanisms. Such findings indicate that CBG may influence cellular inflammatory signaling under experimental conditions.
Interpretation requires caution. Many mechanistic studies involve cell culture systems or animal models, which cannot be directly extrapolated to human therapeutic outcomes.
The significance of these findings lies primarily in identifying biological pathways affected by cannabinoids, rather than establishing clinical efficacy.
The Gut–Brain Axis
The gut–brain axis describes the bidirectional communication network linking the gastrointestinal tract and the central nervous system. Communication occurs through several mechanisms:
• neural signaling via the vagus nerve
• immune signaling
• endocrine pathways
• microbial metabolites
The endocannabinoid system participates in this regulatory network.
ECS components have been identified throughout the gastrointestinal tract, including in:
• enteric neurons
• intestinal epithelial cells
• immune cells within gut-associated lymphoid tissue
Endocannabinoid signaling influences several physiological processes within the digestive system, including:
• intestinal motility
• secretion
• visceral sensation
• inflammatory signaling
Disruptions of ECS signaling have been investigated in connection with gastrointestinal disorders such as inflammatory bowel disease and functional bowel disorders.
Phytocannabinoids may influence this system indirectly through receptor modulation or through interactions with endogenous cannabinoid metabolism. However, the complexity of gut–brain signaling makes definitive conclusions difficult.
The gut–brain axis represents an active area of cannabinoid research because it integrates neural, immune, and metabolic regulation.
Cannabinoid Signaling in Ocular Physiology
The eye contains components of the endocannabinoid system, including cannabinoid receptors and enzymes involved in endocannabinoid metabolism.
Research into cannabinoids and ocular physiology has focused primarily on intraocular pressure (IOP) and optic nerve health.
Elevated intraocular pressure is the primary modifiable risk factor associated with glaucoma. Several cannabinoids have been studied for their potential influence on aqueous humor dynamics and ocular pressure.
Early experimental studies reported reductions in intraocular pressure following administration of cannabinoids. These observations led to investigations examining individual cannabinoids, including CBG.
A study examining cannabigerol administration in animal models reported reductions in ocular tension after repeated dosing. The mechanism remains unclear but may involve modulation of aqueous humor production or trabecular outflow.
More recent reviews of cannabinoid pharmacology note that cannabinoid receptors are expressed in several ocular tissues, including:
• ciliary body
• trabecular meshwork
• retina
• optic nerve
These findings suggest that cannabinoid signaling may influence multiple aspects of ocular physiology.
However, clinical translation remains limited. Controlled clinical studies examining cannabinoids and glaucoma have produced mixed results, and topical delivery challenges complicate therapeutic development.
Consequently, cannabinoid research in ocular physiology remains an active but unresolved area of investigation.
Observational Patterns in CBG Use
Formal dosing guidelines for CBG have not been established through controlled clinical trials. In practical settings, individuals experimenting with cannabinoid formulations often report considerable variability in perceived effects.
One observation reported in cannabinoid formulation contexts involves relative dosing between CBD and CBG when used individually. In some observational cases, individuals appear to use approximately 20–30% more CBG than CBD when comparing the cannabinoids in isolation.
Several factors may contribute to this pattern.
Many CBG-dominant hemp cultivars contain very low THC concentrations, allowing higher cannabinoid quantities within legal THC limits. Differences in receptor pharmacology may also contribute to perceived differences in effective dose.
Such observations should not be interpreted as standardized dosing guidance. They represent informal patterns reported in consumer contexts rather than controlled pharmacological research.
Individual Variability in Cannabinoid Response
Human responses to cannabinoids vary widely. Differences arise from several factors including:
• genetic variation in receptor expression
• metabolic enzyme activity
• endocannabinoid baseline levels
• terpene composition of cannabis extracts
• ratios between cannabinoids within formulations
Anecdotal reports illustrate this variability. Some individuals describe CBG as mildly stimulating or cognitively activating. Others report no such effect and use CBG without disruption to sleep patterns.
Variability is expected for compounds interacting with complex signaling systems such as the ECS. Receptor distribution, downstream signaling cascades, and pharmacokinetic differences all influence physiological responses.
For this reason, interpretation of individual experiences should remain cautious. Observational reports provide useful insights but cannot substitute for controlled clinical data.
References
Kearsey LJ et al. Biosynthesis of cannabigerol and cannabigerolic acid. Synthetic Biology. 2023.
Kim AL et al. Profiling cannabinoid biosynthetic genes in commercial cannabis cultivars. Plants. 2022.
Luo X et al. Complete biosynthesis of cannabinoids in yeast. Nature. 2019.
Russo EB. Cannabigerol and cannabigerolic acid: biosynthesis and pharmacology. Journal of Cannabis Research. 2026.
Nachnani R et al. The pharmacological case for cannabigerol. Journal of Pharmacology and Experimental Therapeutics. 2021.
Di Marzo V et al. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2024.
Jeong GH et al. Anti-inflammatory effects of cannabigerol mediated through JAK/STAT and NF-κB signaling pathways. Cells. 2025.
Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain–gut axis. Gastroenterology. 2016.
Lindner T et al. Therapeutic potential of cannabinoids in glaucoma. Pharmaceuticals. 2023.
Colasanti BK et al. Effects of cannabigerol on ocular pressure in experimental models. Experimental Eye Research. 1984.